Kidney Fibrosis and MRI

Children's Hospital Medical Center, Cincinnati37 enrolled

Overview

The investigators plan a prospective cross-sectional study of pediatric and adult healthy volunteers and patients with chronic kidney disease that will correlate a variety of quantitative MRI biomarkers with severity of renal insufficiency and available histopathology. Over 3 years, the investigators will recruit approximately 20 healthy volunteers, 20 patients with chronic kidney disease (CKD) Stage 2-5, and 20 patients with renal transplant kidneys. The investigators also plan to assess the effect of inflammation on the quantitative MRI biomarkers by recruiting approximately 20 additional patients with active lupus nephritis.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Kidney Diseases

Interventions

Kidney MRIDIAGNOSTIC_TEST

An MRI examination will be completed per research MRI protocol.

Eligibility

Sex: ALLMin age: 10 YearsMax age: 25 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Subjects who meet all of the following criteria will be eligible for the study: 1. ≥ 10 and ≤ 25 years of age and; 2. Kidney transplant patients, who have had a recent kidney biopsy (within 1 year) that shows interstitial fibrosis OR 3. Patients with CKD Stage 2-5 who have previously had a biopsy (within 1 year) OR 4. Lupus patients with active nephritis who will undergo biopsy evaluation before and after induction therapy OR 5. Healthy Controls Exclusion Criteria: Subjects who meet any of the following criteria will be excluded from the study: 1. Known contraindication to MR imaging (e.g., implanted non-MRI compatible device) 2. Known or suspected pregnancy. Female subjects of child bearing potential will undergo a urine pregnancy test prior to imaging. 3. Inability to undergo MRI without sedation/anesthesia. 4. Non-English Speaking

Locations (1)

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

Outcomes

Primary Outcomes

Development of noninvasive MRI methods to measure kidney disease using MR elastography.

Time frame: 3 years

Development of noninvasive MRI methods to measure kidney disease using quantitative T1 mapping.

Time frame: 3 years

Development of noninvasive MRI methods to measure kidney disease using T1rho mapping.

Time frame: 3 years

Development of noninvasive MRI methods to measure kidney disease using T2 mapping.

Time frame: 3 years

Development of noninvasive MRI methods to measure kidney disease using magnetization transfer imaging.

Time frame: 3 years

Development of noninvasive MRI methods to measure kidney disease using diffusion-weighted imaging.

Intra-voxel incoherent motion and diffusion tensor imagining will be measured.

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.